A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia

Thomas S. LinDivision of Hematology and Oncology, The Ohio State University, Columbus, OH, USA

Wendy StockDivision of Hematology and Oncology, University of Chicago, Chicago, IL, USA

Huiping XuDivision of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA

Mitch A. PhelpsDivision of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA

Margaret S. LucasDivision of Hematology and Oncology, The Ohio State University, Columbus, OH, USA

Sara K. GusterDivision of Hematology and Oncology, The Ohio State University, Columbus, OH, USA

Bruce R. BriggsDepartment of Pathology, The Ohio State University, Columbus, OH, USA

Carolyn CheneyDivision of Hematology and Oncology, The Ohio State University, Columbus, OH, USA

Pierluigi PorcuDivision of Hematology and Oncology, The Ohio State University, Columbus, OH, USA

Ian W. FlinnSarah Cannon Research Institute, Nashville, TN, USA

Michael R. GreverDivision of Hematology and Oncology, The Ohio State University, Columbus, OH, USA

James T. DaltonDivision of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA

John C. ByrdDivision of Hematology and Oncology, The Ohio State University, Columbus, OH, USACorrespondence[email protected]

Your download is now in progress and you may close this window